Eucrates Biomedical Acquisition, a blank check company formed by Vedanta Management, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.

The New York, NY-based company plans to raise $100 million by offering 10 million units at $10. Each unit consists of one share of common stock and one-third of a warrant, exercisable at $11.50. At the proposed deal size, Eucrates Biomedical Acquisition would command a market value of $129 million.

The company is led by Chairman Stelios Papadopoulos, who is the Chairman of Biogen, Exelixis, and Regulus Therapeutics and also co-founder of Anadys Pharmaceuticals (acquired in 2011) and Cellzone (acquired in 2012). He is joined by CEO and Director Parag Saxena, the co-founder and CEO of private equity investment management firms Vedanta Management and New Silk Route Advisors. The SPAC plans to target North American and European healthcare companies, specifically those utilizing biomedicine and data science.

Eucrates Biomedical Acquisition was founded in 2020 and plans to list on the Nasdaq under the symbol EUCRU. The company filed confidentially on September 2, 2020. Stifel and H.C. Wainwright are the joint bookrunners on the deal.

The article Healthcare SPAC Eucrates Biomedical Acquisition files for a $100 million IPO originally appeared on IPO investment manager Renaissance Capital’s web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital’s research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital’s Renaissance IPO ETF (symbol: IPO), Renaissance International ETF (symbol: IPOS), or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Source Article

Investors often rely on the healthcare sector to safeguard their investments. This is because demand for healthcare services does not vary much with market conditions. Also, investments in the sector provide sufficient protection to the capital invested.

Many pharmaceutical companies also offer regular dividends. Companies that consistently pay out dividends are financially stable and generate consistent cash flows, irrespective of market conditions. Mutual funds are perfect choices for investors looking to enter this sector since they possess the advantages of wide diversification and analytical insight.

As a matter of fact, the U.S. healthcare sector is anticipated to experience a major revolution in the days to come. The coronavirus pandemic is likely to shape up the future for the space.

In such circumstances, investing in healthcare mutual funds seems prudent. However, choosing the right mutual funds for your portfolio can be quite tricky. To that end, let us find out which of the two funds discussed below is better.

PGIM Jennison Health Sciences Fund- Class A PHLAX

The fund aims for long-term capital appreciation. This non-diversified fund invests majority of its assets in equity and equity-related securities of companies within the health sciences sector, such as pharmaceutical companies, biotechnology companies, medical device manufacturers, healthcare service providers and health maintenance organizations.

Further, the fund also invests in other companies that derive at least half of their revenues or profits from operations in the healthcare sector.

This Sector-Health product has a history of positive total returns for over 10 years. Specifically, the fund’s returns over the three and five-year benchmarks are 11.5% and 7.1%, respectively. To see how this fund performed compared in its category, and other #1 and #2 Ranked Mutual Funds, please click here.

PGIM Jennison Health Sciences Fund- Class A, as of the last filing, allocates its assets in the

Zion Market Researchhas published a new report titled “Healthcare Insurance Market by Provider (Private Providers and Public Providers), by Product (Disease Insurance, Medical Insurance, and Income Protection Insurance), by Provider Network (Preferred Provider Organizations (PPOs), Point Of Service (POS), Health Maintenance Organizations (HMOs), and Exclusive Provider Organizations (EPOs)), by Type (Lifetime Coverage and Term Coverage), and by Demographics (Minors, Adults, and Senior Citizens): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2026”. According to the report, the globalhealthcare insurance marketwas valued at approximately USD 1,010.3 billion in 2017 and is expected to generate revenue of around USD 2,030.1 billion by the end of 2026, growing at a CAGR of around 7.9% between 2018 and 2026.

Medical spending makes poor often vulnerable and results in huge amounts of household spending. Health insurance eliminates or reduces out-of-pocket spending on healthcare solutions and ensures financial risk protection. Government plays a prominent role in deciding the healthcare policies of a country, which directly affects the development of the healthcare insurance market. Supportive government policies is invading the prominent growth of healthcare insurance market, whereas, affordable access to quality treatment and essential medicines depends on several factors, such as provision and use of medicines, sound policies on selection and pricing, efficient regulation by the government and ruling authorities, functioning health infrastructure, a qualified health workforce, good governance, and information systems. Most of the low- and middle-income countries struggle to meet these criteria and fail to provide prominent healthcare services to their population.

Get PDF Sample Copy of this Report to understand the structure of the complete report @https://www.zionmarketresearch.com/sample/healthcare-insurance-market/news

However, the GDP growth has accelerated the expansion of the healthcare insurance market. Healthcare insurance companies are growing mainly due to the emergence of the middle class, rising disposable income, and increasing per capita income globally. The

The MarketWatch News Department was not involved in the creation of this content.

Sep 30, 2020 (Profound via COMTEX) —
The global healthcare personal protective equipment market was valued at USD 5.02 billion in 2019 and expected to reach USD 25.55 billion by 2027 with to register a compound annual growth rate (CAGR) of around 8.12% during period 2020 to 2027.

A recent study by Precedence Research on the Healthcare Personal Protective Equipment market offers a forecast for 2020 and 2027. The study analyzes crucial trends that are currently determining the growth of the Healthcare Personal Protective Equipment market. This report explicates on vital dynamics such as the drivers, restraints, and opportunities for key market players, along with key stakeholders as well as emerging players associated with the manufacturing of Healthcare Personal Protective Equipment. The study also provides the dynamics that are responsible for influencing the future status of the Healthcare Personal Protective Equipment market over the forecast period.

A detailed assessment of the Healthcare Personal Protective Equipment market value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. A list of prominent companies operating in the Healthcare Personal Protective Equipment market along with their product portfolio enhances the reliability of this comprehensive research study.

In this study, the years considered to estimate the market size of Healthcare Personal Protective Equipment are as follows:

  • History Year: 2016-2019
  • Base Year: 2019
  • Estimated Year: 2020
  • Forecast Year 2020 to 2027

Get the Sample Pages of [email protected] https://www.precedenceresearch.com/sample/1060

Report Summary

The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the Healthcare Personal Protective Equipment market across the globe.

A comprehensive estimate on the Healthcare Personal Protective Equipment market has been provided through an optimistic

When Blue KC pulled out there were few options for the 67,000 people affected by the move. But it’s a different scene today. The Kansas City market has become increasingly competitive with several insurers, including Ambetter and Cigna serving local ACA customers, said Abraham, “a fairly decent number of insurers competing.”

“And I think Blue KC probably also has to be thinking about what effect that has on other parts of their insurance, other lines of business, in the bigger picture as these insurers kind of get a foothold in Missouri, and what impact that might have on other types of insurance that Blue KC sells, particularly to employer groups, and to some extent Medicare,” said Abraham.

Blue KC’s Spira Care is currently only available through employers. Members have access to “enhanced primary care centers” in Kansas City’s Crossroads district, Lee’s Summit, Liberty, Olathe, Shawnee, Tiffany Springs and Wyandotte County, and soon in Overland Park.

They’re designed as a one-stop shop where members have access to concierge-style “care guides,” reflecting what Blue KC members said they wanted their health care to look like, said Housley.

“We met with consumers, and some of them were former members on our plans when we were in the ACA, and said what do you want? How could we make health care better?'” said Housley.

Source Article